Equine arteritis virus (EAV) is the causative agent of equine viral arteritis, an apparently emerging disease of equids. In this study, the antibody response of horses to the structural proteins of EAV was evaluated using gradient-purified EAV virions and baculovirus-expressed recombinant EAV structural proteins (G L , G S , M, N) as antigens in a Western immunoblotting assay. Thirty-three sera from horses that previously had been naturally or experimentally infected with EAV were evaluated, including samples from mares, geldings, and both persistently and nonpersistently infected stallions. Sera also were evaluated from 4 horses that had been vaccinated with the commercial modified live EAV vaccine. The data suggest that the serologic response of individual horses to EAV may vary with the infecting virus strain and duration of infection. The M protein was most consistently recognized by the various serum samples, whereas the response to the N and G L proteins was variable and the G S protein was bound by only 1 serum sample. The immunoblotting assay definitively established the protein specificity of the humoral response of horses to EAV; however, it clearly is less sensitive than the standard serum neutralization (SN) test-2 of the 37 sera that were seropositive by the SN test failed to react in the immunoblot assay with any EAV structural protein. Furthermore, the G L protein expresses the known neutralization determinants of EAV, yet only 22 of the 37 sera that had SN antibodies bound the G L protein in the immunoblotting assay. Information from this study will assist ongoing efforts to develop improved methods for the serologic diagnosis of EAV infection of horses.
nucleocapsid of 35 nm that is surrounded by an envelope with cup-like structures. 27, 28 The EAV particle consists of 4 structural proteins, including a phosphorylated nucleocapsid protein (N) and 3 membrane proteins designated M, G S , and G L . 13 The M protein is an unglycosylated protein of 16 kD, and G S and G L are N-glycosylated proteins of 25 and 30-42 kD, respectively. The N, M, and G L proteins are present in the virion in approximately equimolar amounts (3:2:3, respectively), whereas the G S protein is only a very minor component of the virion. 13 The G L protein expresses the known neutralization determinants of EAV. [1] [2] [3] 8, 17, 21 The genome of EAV includes at least 8 open reading frames (ORFs). 11, 16 ORFs 1a and 1b encode the viral replicase, whereas ORFs 2-7 are nested and located at the 3Ј end of the genome. ORFs 2, 5, and 6 encode the G S , G L , and M membrane proteins, respectively, and ORF 7 encodes the N protein. Purified EAV virions and baculovirus-expressed G L , G S , M, and N proteins, as well as virus protein-specific monoclonal (MAbs) and polyclonal antibodies, were utilized in a Western immunoblotting assay in the present study to establish the specificity of the antibody response of EAV-infected horses to the structural proteins of EAV. The serologic response of persistently infected stallions and nonpersistently infected horses was also compared. 
Materials and methods
Viruses and cell culture. A derivative of the original Bucyrus strain of EAV (ATCC VR-796) a was passaged in rabbit kidney (RK-13; ATCC CCL 37) a cells as previously described, 1, 4 and this virus subsequently was used for the preparation of cesium chloride gradient-purified virion preparations 1 and for the cloning of ORFs encoding individual structural proteins of EAV. Spodoptera frugiperda (Sf9) cells, wild-type baculovirus (Autographa californica nuclear polyhedrosis virus; AcNPV), and modified AcNPV virus for cotransfection were obtained from a single commercial source. b Sf9 cells were grown and maintained at 27 C in supplemented Grace's insect medium c containing 10% fetal bovine serum and antibiotics.
Cloning and expression of ORFs 2, 5, 6, and 7 of EAV in baculovirus. ORFs 2, 5, 6, and 7 from the ATCC Bucyrus strain of EAV, along with flanking portions of adjacent ORFs, were amplified using the polymerase chain reaction (PCR) and a commercially available kit. d Synthetic oligonucleotide primers were used to amplify each ORF (Table  1) . Each PCR product was concentrated e and purified f using commercial kits, essentially as previously described. 4 Plasmid manipulations and transformation of Escherichia coli (TOP10FЈ) c were done according to the manufacturer's instructions and as previously described. 42 Each PCR fragment was cut with appropriate restriction enzymes (ORF 2: BglII and EcoRI; ORF 5: BglII and XbaI; ORF 6: PstI and EcoRI; ORF 7: BglII and EcoRI) and cloned into the pVL1392 baculovirus transfer vector, c which also had been cut at the same restriction sites within the multiple cloning site. Following transformation and purification, plasmids containing the entire coding sequence of each ORF (pEAV2, pEAV5, pEAV6, pEAV7) were identified and characterized by restriction enzyme analysis. Restriction enzymes, DNase-free RNase, and T4 ligase were purchased from a single commercial vendor. g The authenticity of the ORF in each recombinant plasmid then was confirmed by sequence analysis of both strands using internal primers. Sequencing was done as previously described 2, 23 with AmpliTaq DNA polymerase, FS, and an automatic sequencer. h Appropriate clones were selected for transfection, and large quantities of each plasmid were purified using a commercial kit. i Sf9 cell monolayers were cotransfected with 0.5 g of linearized AcNPV DNA and 5 g of each EAV recombinant plasmid according to the manufacturer's instructions. b Recombinant viruses subsequently were identified by plaque screening assay, and the authenticity of the protein product of each recombinant virus (Exp. G S , Exp. G L , Exp. M, Exp. N) was confirmed by Western immunoblotting assay using MAbs or monospecific antisera to each protein. Each recombinant virus was plaque purified 3 times prior to use.
Virus protein-specific monoclonal and polyclonal antisera. The production and characterization of MAbs to the G L (MAb 6D10) and N (MAb 3E2) proteins of EAV has been previously described. 1, 3, 35 Polyclonal rabbit antisera to the G S and M proteins of EAV were prepared by immunization of rabbits with synthetic peptides specific for the amino acid sequence of the extreme carboxy terminus of each protein (G S : NH 2 -Cys-Pro-Ser-Arg-Arg-Thr-Ser-Ser-Gly-Thr-Leu-Pro-Arg-Arg-Lys-Ile-Leu-COOH; M: NH 2 -Tyr-Ala-Gly-Arg-Leu-Phe-Ser-Lys-Arg-Thr-Ala-Ala-Thr-Ala-Tyr-Lys-Leu-Gln-COOH). 13 Rabbits initially were immunized by subcutaneous inoculation of 10 mg of peptide conjugated to keyhole limpet hemocyanin in adjuvant j and subsequently boosted 3 times at 3-wk intervals by subcutaneous inoculation of the peptide in Freund's complete or incomplete adjuvant. k Antipeptide sera were collected at 2 wk after the final immunization and characterized by Western immunoblotting assay using baculovirus-expressed EAV proteins and gradient-purified EAV virions.
Equine sera. Sera from 35 horses that were vaccinated or naturally or experimentally infected with EAV were used to characterize the humoral immune response of horses to EAV (Tables 2, 3 ). Thirteen sera were collected from 11 horses at various intervals after they were experimentally infected with different strains of EAV: 6 horses were inoculated with a strain of EAV isolated during the 1984 outbreak of EVA in Kentucky (KY84), 48, 49 individual horses were each inoculated with strains of EAV isolated during the Ohio (Bucyrus) outbreaks of EVA in 1953 (VBS53) 18 and in Kentucky in 1977 (KY77), 38 another horse was inoculated with a strain of EAV isolated in Illinois during the extensive outbreak of EVA in the midwestern USA in 1993 (IL93), 20 and 2 horses were inoculated with an apparently avirulent strain of EAV (CA95) that was isolated from the semen of a persistently infected stallion (J. F. Patton, unpublished data). Sera from 20 horses that previously had been naturally infected with EAV, as determined by serum neutralization (SN) test, also were evaluated: 7 stallions had been confirmed to be persistently infected with EAV by repeated virus isolation from 1462  77E601  193  193  193  379G  401G  403G  198  199  06  9624  9715  5GW  9GW  11GW  588   TB  TB  TB  TB  TB  TB  mixed  mixed  TB  mixed   QH  QH  TB  TB  TB  TB their semen (5 were actively shedding virus in their semen at the time of serum collection and 2 (nonshedders) were not), 4 nonpersistently infected seropositive stallions, and 9 mares. Sera were also evaluated from 4 horses that were vaccinated with the commercial modified live virus (MLV) vaccine. 1 Sera from a number of horses that were seronegative to EAV as determined by SN test were included as controls, including sera that were collected prior to inoculation of some of the experimentally infected horses.
Western immunoblot and microneutralization assays. Gradient-purified EAV and the expressed protein products of the various recombinant baculoviruses (Exp. G S , ORF 2; Exp. G L , ORF 5; Exp. M, ORF 6; Exp. N, ORF 7) were used as antigens in a Western immunoblotting assay. For preparation of purified EAV antigen, the virus was propagated in RK-13 cells, and virions were purified by centrifugation on a continuous (11-33%) cesium chloride gradient at 103,600ϫ g for 17 hr, as previously described. l For preparation of the recombinant EAV proteins, Sf9 cells were infected with each recombinant virus or AcNPV wild-type baculovirus and incubated at 27 C for 72 hr. The cells then were solubilized in solubilization buffer containing a cocktail of protease inhibitors (20 mM Tris HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], containing aprotinin, leupeptin, and pepstatin A [1 g/ml] and phenylmethane sulfonyl fluoride [17 g/ml]). For Western immunoblotting, the various antigens, including purified virions, individual baculovirusexpressed proteins, and appropriate control antigens (solubilized Sf9 cells and AcNPV wild-type baculovirus-infected cells), were mixed with 2ϫ Laemmli sample buffer containing 50 mM dithiothreitol k and run on 12% SDS-polyacrylamide gels with a 4% stacking gel. 33 The proteins were transferred to membranes m and then incubated with individual test sera, and bound EAV protein-specific antibody was detected with biotinylated anti-species serum (goat anti-horse IgG; goat anti-mouse IgG; goat anti-rabbit IgG). n Blots were incubated with avidin-horseradish peroxidase conjugate, n and binding of the test serum was detected by enhanced chemiluminescence o and subsequent autoradiography. To minimize background labeling, the IgG fraction was purified from selected horse sera using an ion-exchange resin. p Neutralizing antibodies to EAV in individual horse sera were detected using a microneutralization assay, as previously described. 1 Titers are reported as the inverse of the final dilution that provided Ͼ50% protection of the monolayer.
Results
Characterization of baculovirus-expressed EAV proteins. The various recombinant baculoviruses all produced authentic EAV proteins, as determined by sequence analysis of the recombinant viruses (data not shown) and western immunoblotting of their expressed EAV proteins (Exp. G S , Exp. G L , Exp. M, Exp. N) with protein-specific antisera and MAbs and comparison with the same proteins in gradient-purified EAV virions (Fig. 1) . The molecular mass of the baculovirusexpressed nonglycosylated M and N proteins was the same as those in virions, whereas the heterogeneously glycosylated G L protein was represented by 2 bands of approximately 25 and 30 kD in the recombinant protein as compared with a single broad protein band of 30-47 kD in virions (Figs. 2, 3) . The G S protein, which also is glycosylated, produced 4 distinct bands between 19 and 27 kD in the recombinant protein, and at least 1 of these bands also was present in the virion preparation. Detailed analysis of the various recombinant proteins will be published elsewhere.
Serologic response of experimentally infected horses. Sera from all horses that were experimentally infected with each of the 5 field strains of EAV had SN antibody titers (16-512) to EAV (Table 2) , as did the 4 sera from horses that were immunized with the commercial MLV vaccine. There were, however, marked differences in the response of different sera to individual structural proteins of EAV, as determined by their responses to recombinant and EAV virion-associated proteins ( Table 2 ). All 13 sera from horses that were experimentally inoculated with field strains of EAV bound the M protein, whereas the 4 sera from horses inoculated with the commercial MLV vaccine did not. Eight of the 13 sera from horses inoculated with field strains of EAV and 3 of 4 sera from vaccinated horses recognized the N protein, although 2 of these sera recognized only the baculovirus-expressed N protein antigen and not the N protein in the EAV virion preparation. The G L protein expresses the known neutralization determinants of EAV, [1] [2] [3] 8, 17, 21 but despite the fact that all 17 sera from the vaccinated and experimentally inoculated horses were positive by SN test, only 8 of these sera bound the G L protein and 3 bound only the G L protein in EAV virions and not the G L protein expressed from baculovirus. None of the sera from experimentally infected horses reacted with the G S protein.
All sera collected from horses inoculated with the KY84 strain of EAV reacted with both the M and N proteins, whereas the horses inoculated with the VBS53, KY77, IL93, and CA95 strains all reacted (CN) , an experimentally infected horse (KY77 is serum from horse no. 77E601, which was inoculated with the KY77 strain of EAV), and 2 naturally infected horses (CA95G is serum from stallion CA95G that was persistently infected with EAV [virus CA95G was isolated from its semen]; no. 25 is serum from a mare that previously was naturally infected with an unknown strain of EAV) against purified EAV virions. Note the different responses of individual animals: serum from horse no. 25 reacts with the G L , M, and N proteins, whereas that of KY77 reacts only with the G L and M proteins, and CA95G reacts only with the G L and N proteins. Molecular mass markers are included at the left. with the M protein but not the N protein. Conversely, sera from the 3 horses that received multiple inoculations of the MLV vaccine reacted with the N protein but not the M protein. These data suggest that the infecting strain of virus can influence the protein specificity of the serologic response of horses to EAV.
Serologic response of naturally infected horses. The serologic response of naturally infected horses to individual recombinant and virion-associated EAV struc-tural proteins differed significantly between animals ( Table 3 ; Figs. 2, 3) . Sera from the 7 persistently infected stallions reacted with the G L , M, and N proteins, although serum from 1 stallion (CA95G) inconsistently and weakly reacted with the M protein (Fig. 3) . The response of the seropositive but nonpersistently infected stallions was more variable; sera from 2 of the 4 stallions evaluated reacted with both the M and N proteins and serum from a third reacted only with the baculovirus-expressed N protein. None of the sera from the nonpersistently infected stallions reacted with the G L protein, although all were seropositive by SN test with titers that ranged from 32 to 256. Sera from all 9 mares that previously were naturally infected with EAV reacted with the M protein, and 7 reacted with the G L protein although 4 of these recognized only the G L protein in EAV virions and not the baculovirusexpressed G L protein. Six of the 9 mare sera reacted with the N protein; however, 4 of these reacted weakly and 1 reacted only with the baculovirus-expressed N protein. Some of this variability in the antibody response of horses that previously were naturally infected with EAV might reflect the different field strains of virus with which they were infected and the various intervals after infection when sera were collected.
Discussion
Individual recombinant baculovirus-expressed and virion-associated proteins of EAV and respective monospecific antisera and MAbs were used in this study to accurately determine the virus-protein specificity of the humoral immune response of horses to the structural proteins of EAV. Although the identity and nature of the structural proteins of EAV now are established, 13 with the notable exception of the undefined protein products of ORFs 3 and 4, the serologic response of horses to these proteins has not previously been comprehensively defined. The protein products of ORFs 3 and 4 are uncharacterized but are predicted to have nonstructural functions. 13, 16 Conflicting and often contradictory descriptions of the proteins of EAV have been provided in previous studies; a considerable number of apparently different virus-specific proteins of molecular masses of 10.5-72 kD have been identified in EAV-infected cells. 12, 13, [28] [29] [30] 52, 53, 56 The problem of accurately determining the specific identity of individual EAV proteins in the immunoblotting assay is magnified by the similar molecular masses of the G L and G S proteins and of the N and M proteins. The variable glycosylation of the G L and G S proteins 13 and dimerization of the envelope proteins further confuses identification of the structural proteins of EAV. Specifically, the G S protein can exist as a monomer or homodimer, and the G L protein can exist as a monomer or heterodimer complexed with the M protein. 11, 14, 15 Dimerization and the variable glycosylation of the G S and G L proteins can differ depending on the cell system in which the proteins are produced, leading to different forms of each protein with different migration profiles. The situation is even more confusing if EAVinfected cell lysates are used as an antigen source for immunoblotting, because nonstructural proteins such as the replicase and putative protein products of ORFs 3 and 4 also are produced in EAV-infected cells, and there is considerable posttranslational cleavage of the replicase protein in particular. 54 The availability of recombinant structural proteins coupled with their respective monospecific antisera was prerequisite to definitive characterization of the specificity of the antibody response of horses to EAV.
The response of some sera to the N and G L proteins differed depending on whether each protein was included in purified EAV virions or derived by baculovirus expression. A number of sera reacted with the baculovirus-expressed N protein but not with the virion-associated form, perhaps because of a higher concentration of N protein in the recombinant antigen. In distinct contrast, more sera reacted with the G L protein in virions than with the recombinant protein derived from baculovirus. The G L protein derived by baculovirus expression from insect cells also differed in molecular mass from that in virions, perhaps reflecting differing degrees of glycosylation of the protein in the 2 systems. The relative insensitivity of the recombinant G L protein as an antigen in the immunoblotting assay further suggests that the baculovirus-expressed G L protein differs antigenically from the same protein in its virion-associated form, although the nature of these differences currently is uncharacterized because the expressed G L protein strongly reacts with a variety of neutralizing monoclonal and polyclonal antisera.
Both quantitative and qualitative differences were apparent in the response of individual horses to the structural proteins of EAV, perhaps reflecting the infecting strain of virus and the interval following infection. Sera from the 7 persistently infected stallions, regardless of whether or not they were actively shedding virus in their semen, consistently bound the G L , N, and M proteins, although the response of 1 stallion to the M protein was very weak and inconsistently detected (Fig. 3) . In contrast, all but 2 (24/26) convalescent sera from mares, geldings, and stallions that did not become persistently infected following experimental or natural EAV infection recognized the M protein, whereas the response to both the N and G L proteins was more variable (17/26 and 15/26, respectively). These data suggest that the serologic response of persistently infected stallions differs from that of horses that rapidly clear the virus following acute infection. Prolonged exposure to viral proteins during persistent infection of the stallion presumably would be responsible for these differences. Other differences among the responses of individual animals might reflect the infecting virus strain, e.g., all horses inoculated with the KY84 strain of EAV reacted with the N protein, whereas those inoculated with VBS53, KY77, IL93, and CA95 did not. The response of horses vaccinated with the ARVAC vaccine also was quite different from that of horses that were naturally or experimentally infected with other strains of EAV.
The SN test is the standard regulatory test for serologic detection of EAV infection of the horse, although enzyme-linked immunosorbent assays (ELI-SAs) recently have been developed, including 1 that utilizes recombinant N protein as an antigen. 9 In another very recent study, the immunoblotting of N and M proteins expressed in a procaryotic expression vector gave results identical to those obtained by SN test with 32 sera from horses that were either vaccinated against EAV or inoculated with field strains of the virus. 32 The immunoblotting assay described in the present study provides definitive data on the protein-specificity of the humoral immune response of horses exposed to EAV; however, this assay clearly is less sensitive than the existing SN test-2 of the 37 sera that were positive by SN test failed to react with any structural EAV protein in the immunoblotting assay. Furthermore, a number of sera that had significant titers of neutralizing antibody as determined by SN test did not bind the G L protein in the immunoblotting assay despite the fact that the G L protein expresses the known neutralization determinants of EAV. [1] [2] [3] 8, 17, 21 However, the immunoblotting assay described here is very useful in confirming the protein specificity of antibodies in horse serum, and the data strongly suggest that the M protein should be targeted for future development of an improved diagnostic ELISA for serologic detection of EAV infection of horses. Furthermore, the immunoblotting assay has potential diagnostic utility. There is considerable antigenic variation among field strains of EAV, 2 and the SN test, which clearly is serotype-specific, might not detect prior infection of horses with phenotypically novel variants of EAV. 55 
